The Impact of Serum Uric Acid on the Progression of Amyotrophic Lateral Sclerosis in Adults Aged 18 and Older: A Systematic Review.
als
amyotrophic lateral sclerosis
biomarker
disease progression
urate level
uric acid
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
03
06
2023
accepted:
22
07
2023
medline:
24
8
2023
pubmed:
24
8
2023
entrez:
24
8
2023
Statut:
epublish
Résumé
We have conducted this review to see if serum uric acid (UA) is associated with slowing amyotrophic lateral sclerosis (ALS) progression in adult patients who are at least 18 years old. Understanding the effects of this biomarker for future use is critical because of its easy accessibility. This systematic review paper examined five previous years of recent studies and reports, published in English and limited to human investigations from the Cochrane, PubMed, and Google Scholar databases. Using instruments for assessing the eligibility and quality of systematic and narrative reviews, we narrowed our search to 11 reports that show evidence of a positive association between high blood uric acid and the progression of ALS. However, this claim still needs confirmation by future studies to confirm that possibility. The results of this systematic review may provide a strong foundation for future studies on this biomarker, demonstrating the significance of blood uric acid levels in ALS and highlighting the necessity of using that biomarker to track the disease's progression.
Identifiants
pubmed: 37614251
doi: 10.7759/cureus.42312
pmc: PMC10444204
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e42312Informations de copyright
Copyright © 2023, Hussein et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Neurol Neurosurg Psychiatry. 2016 Jun;87(6):611-9
pubmed: 26283685
Adv Drug Deliv Rev. 2009 Nov 30;61(14):1299-315
pubmed: 19716390
Front Public Health. 2022 May 27;10:899027
pubmed: 35692305
Front Neurol. 2021 Mar 11;12:602663
pubmed: 33776880
Front Neurosci. 2019 Dec 06;13:1310
pubmed: 31866818
Proc Natl Acad Sci U S A. 1981 Nov;78(11):6858-62
pubmed: 6947260
Front Neurol. 2021 Dec 06;12:789840
pubmed: 34938266
Eur J Neurol. 2010 Oct;17(10):1298-303
pubmed: 20402747
Antioxidants (Basel). 2021 Jun 23;10(7):
pubmed: 34201812
Intern Med. 2012;51(12):1501-8
pubmed: 22728481
Redox Rep. 2022 Dec;27(1):79-84
pubmed: 35296219
Int J Surg. 2021 Apr;88:105906
pubmed: 33789826
Amyotroph Lateral Scler Frontotemporal Degener. 2019 Feb;20(1-2):53-60
pubmed: 30784318
Sci Rep. 2018 Jan 18;8(1):1100
pubmed: 29348425
Clin Neurol Neurosurg. 2021 Apr;203:106566
pubmed: 33706058
Front Psychiatry. 2022 Apr 22;13:828476
pubmed: 35530021
Lancet Neurol. 2013 Apr;12(4):368-80
pubmed: 23518330
Muscle Nerve. 2018 Mar;57(3):430-434
pubmed: 28857199
Neurotherapeutics. 2017 Jan;14(1):148-153
pubmed: 27995438
Oxid Med Cell Longev. 2019 Jun 9;2019:1712323
pubmed: 31281567
Ann Clin Transl Neurol. 2019 Jan 31;6(3):486-495
pubmed: 30911572
Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):194-200
pubmed: 29277115
Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):608-19
pubmed: 18600514
Biomedicines. 2021 Aug 17;9(8):
pubmed: 34440231